Ocular Therapeutix Inc. - notizie pubblicate 213 - letture 2.974
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Material Event - Form 8-K
Item 8.01. other events. on january 25, 2024, ocular therapeutix, inc. (the "company") announced that the u.s. food and drug administration (the "fda") had agre ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
Spa amendment expands eligibility criteria for sol clinical trial broadening of eligibility criteria anticipated to accelerate overall trial enrollment bedford, mass., jan. 25, 202 ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Bedford, mass., dec. 18, 2023 (globe newswire) -- ocular therapeutix™, inc. (nasdaq: ocul) (the "company"), a biopharmaceutical company focused on the formulation, deve ...
OCULAR THERAPEUTIX INC.
Supplemental Prospectus - Form 424B5
Tm2332583-4_424b5 - none - 7.6094155s table of contents filed pursuant to rule 424(b)(5) registration no. 333-275373 prospectus supplement (to prospectus dated november 16, 2023) 3 ...
OCULAR THERAPEUTIX INC.
Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock - Form 8-K
Ocular therapeutixtm announces pricing of public offering of common stock bedford, mass, december 13, 2023 - ocular therapeutix™, inc. (nasdaq: ocul) (the "company"), a ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
Bedford, mass., dec. 13, 2023 (globe newswire) -- ocular therapeutix™, inc. (nasdaq: ocul) (the "company"), a biopharmaceutical company focused on the formulation, deve ...
OCULAR THERAPEUTIX INC.
Supplemental Prospectus - Form 424B5
Tm2332583-1_424b5 - none - 7.0312792s table of contents the information in this preliminary prospectus supplement is not complete and may be changed. a registration statement relat ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
Bedford, mass., dec. 13, 2023 (globe newswire) -- ocular therapeutix™, inc. (nasdaq: ocul) (the "company"), a biopharmaceutical company focused on the formulation, deve ...
OCULAR THERAPEUTIX INC.
Notice of Effectiveness - Form EFFECT
Notice of effectiveness united states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: november 16, 2023 4:30 p.m. form: s-3 ci ...
OCULAR THERAPEUTIX INC.
Registration Statement - Specified Transactions - Form S-3
Tm2329877-1_s3 - none - 5.8750318s table of contents as filed with the securities and exchange commission on november 7, 2023 registration no. 333- united states securities and exc ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update - Form 8-K
Ocular therapeutix™ provides third quarter 2023 financial results and corporate update fda agrees to overall design of the first pivotal trial for axpaxli in wet amd under a spec ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti